Navigation Links
ChartTrends(R): Bone and Mineral Metabolism in Dialysis Reveals Latest Trends in the Treatment of Calcium, Phosphorus and PTH
Date:4/30/2009

EXTON, Pa., April 30 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends(R): Bone and Mineral Metabolism in Dialysis, a syndicated publication offering comprehensive insight into the management of calcium, phosphorus and PTH in dialysis patients. The report is based on actual patient and laboratory data collected in February 2009 from approximately 1,000 dialysis patient charts.

This ChartTrends(R) report sheds light on patient demographics, laboratory values, and treatment prevalence with phosphate binders, Nutritional Vitamin D, Active Vitamin D and Sensipar. Moreover, it provides information on the interplay between these therapies and uncovers actual (as opposed to self-reported) product dosing and titration, brand switching and reasons for switching, as well as brand persistency.

In the treatment of hyperphosphatemia, patients tend to be initiated on phosphate binder monotherapy when phosphorus reaches 5.7 mg/dL. Phosphorus levels are significantly higher when combination therapy is initiated. Contrary to what Nephrologists perceive based on self-reported data, combination binder therapy is prescribed infrequently. Genzyme's sevelamer is the market share leader despite the fact that it has the highest pill burden. Shire's Fosrenol has the lowest pill burden, but significantly lower persistency compared to Renagel, Tums and FMC's PhosLo. Within the sevelamer franchise, patient conversion to Renvela stands at about 27% and about half of the Renvela patients had been switched from Renagel.

The vast majority of dialysis patients are on Active Vitamin D formulations such as Abbott's Zemplar and Genzyme's Hectorol. The use of Nutritional Vitamin D (i.e. ergocalciferol) appears to be increasing and the concomitant use of Nutritional Vitamin D does have an impact on the dose of Active Vitamin D. Although the use of Active Vitamin D is widespread, a substantial number of patients are still above the target level for iPTH.

Amgen's Sensipar tends to be reserved for difficult to control patients and is initiated at a mean iPTH of 669 pg/mL, with more than one-quarter of patients being initiated when iPTH >750 pg/mL. Although MD perception is that treatment with Sensipar can result in lower doses of Vitamin D and phosphate binders, the converse is actually true. Patients treated with Sensipar tend to be on higher doses of both agents. Despite more aggressive therapy, a significant proportion of these patients remain uncontrolled.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New property found in ancient mineral lodestone
2. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
3. New insight to demineralization
4. Sea urchin yields a key secret of biomineralization
5. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
6. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
7. AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers
8. Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert
9. Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert
10. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
11. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... 2017 , ... Baltimore biotech firm, PathSensors, announced that its ... developing and issuing recommendations to grow Maryland's biohealth industry and position the state ... , The recommendations are contained in a report from the Maryland ...
(Date:5/19/2017)... ... May 19, 2017 , ... In response to the strong base of evidence ... Inc. announces the release of their Gait Trainer 3 with an Integrated Music Therapy ... system to aid in rehabilitating individuals with cerebral palsy, traumatic brain injury, stroke and ...
(Date:5/18/2017)... ... ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio company, ... has doubled in size over the past six months with the acquisition of businesses ... joins CSM as Chief Financial Officer. Roger has over 25 years of experience ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM ... firm for the life sciences and healthcare industries, is honored that Jay ... Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role in ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):